Untreatable conditions can be helped with reprogrammed adult stem cells
In just two years, the celebrated adult stem cell researcher Shinya Yamanaka hopes that clinical trials will begin on curing the once-untreatable spinal injuries with the help of “reprogrammed” adult cells or ‘induced pluripotent stem' (iPS) cells.
Animal trials have shown promising results of transplanting iPS cells to treat paralytic spinal injury, said Professor Yamanaka, delivering a lecture on “New Era of Medicine with iPS Cells” here on Monday.
The lecture was organised as part of the Cell Press-TNQ India Distinguished Lectureship Series.
Prof. Yamanaka, who started his career as a physician 25 years ago and “tried to be an orthopaedic surgeon”, said: “I soon realised I was not so good at surgery. I also realised that even a good surgeon can't help many patients suffering from untreatable diseases and injuries.”
This inspired him to change his career and get back to studying “basic medicine”.
That's where he “met” the iPS cell, which led him to his major scientific breakthrough in 2007 allowing him to “reprogramme” adult human skin cells into embryonic-like stem cells.
The iPS cells have revolutionised research on regenerative medicine: they are free from debates over ethics — often raised in the use of human embryos — and reduce the risk of tissue rejection after transplant. Once established, these cells can be used to elucidate disease mechanisms and to screen drugs.
But creating these cells is both time and money-consuming, he said.
It costs as much as U.S. $ 1 million to treat just one patient, and takes six to eight months to generate, expand and induce differentiation in iPS cells.
“In the case of spinal injuries, we have to transplant the cells within a month after the injury.
“To overcome this, we think it makes sense to create and maintain an iPS cell bank from healthy individuals,” he said.
The risk of rejection by an individual's immune system can be minimised by matching donors with HLA (human leucocyte antigen), a form of “blood type” for human cells.
In Japan, for instance, just 75 unique HLA homozygotes would match 80 per cent of the population, he explained.
Prof. Yamanaka, who was awarded the Albert Lasker Prize in 2009 and the Wolf Prize in 2011, later answered questions from budding biologists and veteran scientists in the audience.
He will speak next in Chennai on February 1 and New Delhi on February 3 as part of the lectureship series.
From: Nelson, Timothy J., M.D., Ph.D.There are iended clinical trials currently ongoing throughout the world thatfocuses on heart disease and stem cell treatments. Although these clinicaltrials have yet to be established as the standard of care , manyinvestigators and patients are actively contributing to these emergingstudies. Mayo Clinic has established a Regenerative Medicine Consult Serviceto better address the specific questions of patients regarding stem celltherapies with the goal of linking patients to the proper clinical trials.The Regenerative Medicine Consult Service within the Transplant Center atMayo Clinic Rochester would be able to provide current updates on thesetopics.The number for Dr. Nelson's appointment coordinator in the Regenerative Medicine Consult Service is 8-5908.Her name is Sarah Bruggeman.
Sir,
I am proud of your inventions and grateful to you for your harvest on leaning diseases. As your findings helps spinal cord injury persons, I expect that your finding would also help cerebral palsy children. I hope so. As I am the mother of cerebral palsy child 10 years old whose, left eye, left hand and left leg are effected is waiting for a bright future after a treatment through ploripotent cells. If ever it is possible please publish it with our government's approval for treatment. So that more number of families will be benefited with this treatment. Our grateful thanks giving will always be to you. Please do the need ful.
Please Email the Editor